TY  -  
T1  - Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin 
SN  -  /  
UR  - http://hdl.handle.net/10138/325866 
T3  -  
A1  - Lehtisalo, Minna; Keskitalo, Jenni E.; Tornio, Aleksi; Lapatto-Reiniluoto, Outi; Deng, Feng; Jaatinen, Taina; Viinamäki, Jenni; Neuvonen, Mikko; Backman, Janne T.; Niemi, Mikko 
A2  -  
PB  -  
Y1  - 2020 
LA  - eng 
AB  - Xanthine oxidase inhibitors febuxostat and allopurinol are commonly used in the treatment of gout. Febuxostat inhibits the breast cancer resistance protein (BCRP) in vitro. Rosuvastatin is a BCRP substrate and genetic variability in BCRP markedly affects rosuvastatin pharmacokinetics. In this study, we investigated possible effects of febuxostat and allopurinol on rosuvastatin pharmacokinetics. In a randomized crossover study with 3 phases, 10 healthy volunteers ingested once daily placebo for 7... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - DRUG-DRUG INTERACTION; HEPATIC-UPTAKE; ABCG2 BCRP; PHARMACOKINETICS; TRANSPORTER; GOUT; ELTROMBOPAG; OATP1B1; RISK; ATORVASTATIN; 3111 Biomedicine; 3121 General medicine, internal medicine and other clinical medicine 
N1  -   
PP  -  
ER  -